Detalhe da pesquisa
1.
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
BMC Cancer
; 19(1): 165, 2019 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30791870
2.
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Cell Oncol (Dordr)
; 47(1): 189-208, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667113
3.
Insights into cisplatin-induced neurotoxicity and mitochondrial dysfunction in Caenorhabditis elegans.
Dis Model Mech
; 15(3)2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35107130
4.
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
Clin Cancer Res
; 28(6): 1217-1228, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965950
5.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
EBioMedicine
; 83: 104205, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35985932
6.
Double pigtail for preventing ascending cholangitis after endoscopic ultrasonography-guided choledochoduodenostomy with lumen-apposing metal stent.
Dig Endosc
; 28(1): 100, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26354292
7.
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Front Oncol
; 11: 645026, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307126
8.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
; 9: 707, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31448227
9.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
; 9: 967, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31598491